Patents by Inventor Joyee Antony George

Joyee Antony George has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
    Publication number: 20240124549
    Abstract: Fusion proteins include an extracellular domain of PD1 protein (programmed cell death protein-1) and/or an extracellular domain of PD-L1 protein (programmed cell death-ligand 1 protein (CD274 or B7-H1)). Portions of the extracellular domains are expressed in specific configurations and purified as protein, which are used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. A method is for determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient when the patient has undergone at least one dose of immunotherapy.
    Type: Application
    Filed: December 21, 2023
    Publication date: April 18, 2024
    Inventors: Jody BERRY, Elizabeth BOOTH, Joyee ANTONY GEORGE, Elisabete NASCIMENTO, Daniel NAGORE CASAS
  • Immunoassays and engineered proteins for monitoring antibody treatments to the immune checkpoint inhibitors PD1 and PD-L1
    Patent number: 11919938
    Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: March 5, 2024
    Assignee: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: Jody Berry, Elizabeth Antony Booth, Joyee Antony George, Elisabete Nascimento, Daniel Nagore Casas
  • IMMUNOASSAYS AND ENGINEERED PROTEINS FOR MONITORING ANTIBODY TREATMENTS TO THE IMMUNE CHECKPOINT INHIBITORS PD1 AND PD-L1
    Publication number: 20200299353
    Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
    Type: Application
    Filed: November 29, 2018
    Publication date: September 24, 2020
    Applicant: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: JODY BERRY, ELIZABETH Antony BOOTH, JOYEE ANTONY GEORGE, ELISABETE NASCIMENTO, DANIEL NAGORE CASAS
  • Antibodies against
    Patent number: 10117933
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: November 6, 2018
    Assignee: EMERGENT BIOSOLUTIONS CANADA INC.
    Inventors: Jody Berry, Cory Nykiforuk, Darrell Johnstone, Joyee Antony George
  • Clostridium difficile antibodies
    Patent number: 9994630
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: June 12, 2018
    Assignee: CANGENE CORPORATION
    Inventors: Jody Berry, Darrell Johnstone, Joyee Antony George, Bonnie Tighe
  • Clostridium Difficile Antibodies
    Publication number: 20170051047
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Application
    Filed: October 31, 2016
    Publication date: February 23, 2017
    Inventors: Jody Berry, Darrell Johnstone, Joyee Antony George, Bonnie Tighe
  • antibodies
    Patent number: 9505847
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: November 29, 2016
    Assignee: CNJ HOLDINGS INC
    Inventors: Robyn Cassan, Jody Berry, Darrell Johnstone, Derek Toth, Joyee Antony George, Bonnie Tighe
  • ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE
    Publication number: 20150290319
    Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin B. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
    Type: Application
    Filed: November 29, 2013
    Publication date: October 15, 2015
    Inventors: Jody Berry, Robyn Cassan, Darrell Johnstone, Laura Saward, Joyee Antony George